EXETER, England, November 15 /PRNewswire/ -- Mobious Genomics, in association with Mobious Biosystems, is pleased to announce the availability of its ExtendaSeq(TM) chemistry plug-in for next generation Sequencing-by-Synthesis chemistry platforms. This chemistry, invented by Mobious’s founder Daniel Densham will greatly increase the utility and value of existing next-generation sequencing chemistries via read length extension.
The ExtendaSeq(TM) chemistry plug-in allows currently available next generation SBS chemistry platform read lengths to be extended by a factor of ten times or greater.
Daniel Densham, managing director of Mobious Biosystems, owner of the Extendaseq(TM) and partner company Mobious Genomics commented:-
“Next Generation sequencing platforms and their associated chemistries are rapidly gaining traction in the commercial life science market. This is mainly happening as high levels of sample parallelisation deliver drastic cost reductions. However, as these technologies are increasingly applied to the high-value field of sequence discovery (De Novo) sequencing, rather than to less demanding re-sequencing applications, read length is rapidly becoming one of, if not the most important performance characteristics of next generation sequencing methods. Mobious is therefore understandably excited about the forthcoming commercial application of our ExtendaSeq(TM) chemistry plug-in”.
The ExtendaSeq(TM) chemistry plug-in is suitable for a number of third party chemistry platforms, including as those sold by 454 Corporation, Solexa and Helicos. Further, a new version of the plug-in currently under development, the ExtendaSeq-ligate(TM), is designed to significantly increase the read lengths of ligation based chemistries, such as those being developed by Applied Biosystems/Agencourt Personal Genomics.
Notes to Editors
Mobious Genomics is pioneering the development of fundamentally new technologies in the fields of genetic analysis and proteomics.
By unifying biological molecular systems and artificial nanostructures, Mobious has created a range of next generation diagnostic and research tools, able to materially outperform current platforms at a fraction of the cost. The group’s research has resulted in new technologies and IP in such fields as single molecule sequencing, sequencing by synthesis, ultra highly multiplexed real-time PCR and affinity acceleration for biochips.
Mobious believes that its technology has the potential to help transform the acquisition and use of genetic knowledge in the global healthcare and detection industries.
For more information please contact: Daniel Densham, Mobious Genomics +44(0)8700-112-500 licenseportal@mobious.comwww.mobious.com
Mobious Genomics
CONTACT: For more information please contact: Daniel Densham, MobiousGenomics +44(0)8700-112-500, licenseportal@mobious.com, www.mobious.com
